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Charcot arthropathy of the foot is a rare but devastating complication of diabetes that remains to be a
challenging issue for the foot and ankle surgeons. Charcot foot fails to be an obvious diagnostic option that
comes to mind, even in a pathognomonic clinical appearance. The rarity of the disorder, more common
pathologies that mimic the condition, and the self-limiting prognosis deviate the clinician from the right
diagnosis. The clinical challenges in the diagnosis of Charcot foot require in-depth investigations of its
enigmatic nature to establish useful guidelines. Yet, this goal seems to be beyond reach, without a holistic
view of the immense literature concerning the pathophysiology of the disorder. The primary objective of this
article is to put together and review the recent advancements about the etiology and intrinsic mechanisms
of diabetic Charcot foot.
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europathic arthropathy, also referred as Charcot
arthropathy which was named after French
neurologist Jean-Martin Charcot (18251893),
is a progressive, denervation-induced degeneration of the
foot and ankle joints (1). Considering devastating out-
comes, such as eventual deformity which is almost always
inevitable when untreated, the etiology and pathophysio-
logy of this insidious disorder is vigorously studied in
the literature as one of the core topics (2). A significant
amount of content is amassing in the literature about
this topic and this may be a sign of unclarity about
the pathophysiology of Charcot arthropathy. Although
numerous factors have been attributed as a contributor,
the big picture is still not fully revealed.
A variety of causes are held responsible for triggering,
amplifying, and converting the inflammatory processes
which appears to be the major suspect at hand (3). Firm
evidence was set forth that proinflammatory cytokines,
especially the receptor activator of the nuclear factor-kB
(RANK) ligand (RANKL) system is responsible for
abnormally intense osteoclastogenesis (4). Increased
osteoclastic activity is indicated for the excessive and
unsupported bone turnover (5). The reciprocal relation-
ship between the inflammation and repetitive traumas
due to sensorial neuropathy has been substantially
revealed. Yet, the rarity of the condition, its asymmetric
involvement and its self-limiting progress still remain
enigmatic (6). The purpose of this review is to put
together asunder pieces of literature that aim to explain
the condition from different perspectives and to develop
a holistic approach to enlighten the nature of the
inflammatory modulation.
Discovering the underlying disorder is a matter of ut-
most importance. When the diagnosis is Charcot arthro-
pathy, in addition to meticulous treatment of the affected
joint, the main goal should be the cure of the primary
cause, if possible. Traumatic injuries (spinal cord injuries,
peripheral nerve injuries), infections (syphilis, leprosy,
yaws), disorders of neurological structures (myelomenin-
gocele, syringomyelia, spina bifida), neurodegenerative
diseases (amyloid neuropathy, neuropathies secondary to
alcoholism and vitamin deficiency) or other neurological
disorders such as congenital insensitivity to pain syn-
drome, steroid intake (post-renal transplant arthropathy,
intra-articular steroid injections), and heavy-metal poi-
soning belong to the same cluster of diseases leading
to destruction of afferent proprioceptive fibers (717).
This is the core phenomenon that causes subsequent
repetitive traumas to remain unrecognized. After numer-
ous minor or major traumatic injuries, progressive wear
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that eventually end up in massive joint destruction with
characteristic clinical presentation (Figs. 1 and 2) (17, 18).
However, recent studies demonstrated that the loss of
proprioception is not the only etiological factor that leads
to Charcot arthropathy (19). The intervention of certain
external factors, usually unrecognized or irrelevant to the
diabetes, or any other predisposing disease, is a factor
that leads to a local increase in blood flow. Therefore,
the patient’s peripheral circulation should be capable of
vasodilatating despite widespread atherosclerosis, which
explains why Charcot foot is frequent in a relatively
younger population. In summary, to develop a Charcot
syndrome, it is understood that a patient should have a
peripheral neuropathy to enhance a local inflammation
that is triggered by a minor injury, infection, operation,
or an earlier ulceration (1, 20).
Presently, diabetes is recognized as one of the most
common cause of denervation-induced arthropathy
worldwide (18, 2023), the exception is for leprosy, which
appearstobea morecommoncauseoftheCharcotfootin
endemicareas(6,7,24).In theEuropeanDiabetesCenters
study of complications in patients with insulin-dependent
diabetes mellitus (EURODIAB IDDM), in which a con-
siderable number of diabetic patients were included, the
overall prevalence of neuropathy was 28% (25). Never-
theless, the incidence of Charcot arthropathy is relatively
rare, even in neuropathic patients. Charcot arthropathy’s
estimated prevalence is approximately 1% of all neuro-
pathic patients (20). Addressing this rarity, Jeffcoate
explains that Charcot arthropathy develops or progresses
in a small subset of patients where a number of predis-
posing factors coexist (26). The prevalence of diagnosed
Charcot arthropathy in patients with diabetes is reported
to be 0.087.5% (3). However, some studies suggest higher
prevalence with as many as 13% of all diabetic patients
and 29% of the neuropathic patients affected (22, 27).
Due to the lack of specific markers or diagnostic criteria
and Charcot artropathy’s clinical resemblance to rela-
tively more common disorders such as osteomyelitis, the
diagnosis is missed or delayed in 25% of the cases (28).
Yet, an increase in the incidence of Charcot arthropathy
has been reported in recent studies. This increase can
be explained by the progress made at the diagnostic
modalities, the rising awareness of the condition amongst
the physicians and caregivers, and the decreasing rate
of lower limb amputations due to improved hospital
cares (24).
A prospective study conducted in Singapore with
202 diabetic patients revealed that 42.1% of the patients
had sensory neuropathy and 2% of them had Charcot
arthropathy (29). The incidences of Charcot foot in type
1 and type 2 diabetes do not differ, although osteopenia,
as a predisposing factor, appears to be more prevalent
in type 1 (18, 20). However, Petrova et al. reported a
difference in the presentation of Charcot arthropathy at
type 1 and type 2 diabetic patients. In a more recent study,
the same authors emphasized a relative preponderance of
type 1 diabetes compared with type 2 (18, 30). Although
the unilaterality of the condition is emphasized in many
clinical studies, acute Charcot arthropathy is reported
as bilateral in 9% of the patients (31). Moreover, after
prospective computerized tomography examinations,
bilateral neuroarthropathic changes are demonstrated in
75% of Charcot patients (17). Chisholm and colleagues
suggest that obesity is also a predisposing factor for
Charcot arthropathy since at least two thirds of Charcot
patients are obese (22, 32).
Trauma is the most common etiological factor encoun-
tered in the pathogenesis of Charcot arthropathy and was
reported to be present in 2253% of the cases (6, 17, 18).
Capillary leakage and subsequent formation of edema is
the physiological response to blunt trauma (33). A higher
energy trauma causes a disruption of marrow trabeculae
Fig. 1. A 53-year-old diabetic female patient with a Charcot foot.
(Source: Archives of Istanbul University, Cerrahpas ¸a Medical Faculty, Department of Orthopedics and Traumatology.)
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tion to marrow spaces, hence a bone bruise. When this
condition occurs in the foot of a non-diabetic patient, it is
painful and following the cessation of ambulation, local
inflammation of the foot subsides. But in a neuropathic
patient, the insensitive foot does not exhibit pain as
appropriate. Thus, lack of required immobilization flares
up the inflammatory cycle (26).
Osteomyelitis and surgery may initiate Charcot arthro-
pathy in predisposing backgrounds (34). As mentioned
before, osteomyelitis can imitate the clinical appearance
of Charcot arthropathy and consequently lead to mis-
diagnosis and under-treatment. One third of the diabetic
foot infections are complicated by osteomyelitis which is
due to direct contamination from a soft, tissue ulcer (35).
Osteomyelitis manifests with local inflammation and pro-
gressive destruction of the bone which in turn intensify
the proinflammatory cascade.
Local surgery of the foot is suggested as one of the
triggering factors of Charcot arthropathy (26, 36). Arm-
strong et al. retrospectively observed data from 55 acute
Charcot arthropathy patients and reported that 4% of the
patients had recent foot surgery as the only etiological
factor (31). Charcot arthropathy may also follow injudi-
cious immobilization after surgery, a long period of bed
rest or casting (18). Disobedience to a forbidden weight
bearing after foot surgery is also underlined in a case
report as a possible cause of Charcot arthropathy (36).
Charcot arthropathy has also been reported following
a simultaneous pancreas-kidney transplantation (SPKT)
(37). In a more recent study where data from 130 SPKT
patients without any previous history of Charcot arthro-
pathy were analyzed retrospectively, six patients (4.6%)
were diagnosed de novo Charcot arthropathy during the
first year of transplantation where high glucocorticoid
intake was the main factor leading to bone resorption
and myofibril proteolysis (37).
Pathophysiology
The well-respected neurotraumatic and neurotrophic
theories have been relied on for a long time in order to
clarify the pathogenesis of Charcot arthropathy. But
none of these theories can explain this pathogenesis by
themselves. Nevertheless, as the research advanced,
neither the neurotrophic theory which was represented
by Charcot himself (22) nor the neurotraumatic theory
which was supported mainly by German scientists,
have lost value. On the contrary, as complex biochemical
processes revealed, the pathways of the two theories
became more and more intertwined (22, 27).
Charcot, who first studied disturbed physiological
processes that end up to neuropathic arthropathy, pre-
sented the neurovascular theory (38). He believed that
irritation of the ‘trophic’ or vasomotor nerve centers
caused an alteration of bone and joint nutrition. This
theory has been carried further by his supporters, and
now it suggests that autonomic neuropathy disregulates
smooth muscle tonus on the arterial wall. Thus, it leads
to a failure in vasoregulation and an increase in blood
flow to the bone. Monocytes and osteoclasts storm the
affected site and this accelerates the bone resorption rate
resulting in osteopenia. Lower structural resistance cause
minor traumas to end up in fractures, dislocations, and
jointcollapses(22). Volkman andVirchowconfrontedthis
theory, suggesting an insensate foot is prone to repetitive
unrecognized traumas (38). In addition to this, loss of
proprioception disables the protective factors and causes
an abnormal joint loading. Multiple traumas and
Fig. 2. A 61-year-old diabetic male patient with a Charcot foot.
(Source: Archives of Istanbul University, Cerrahpas ¸a Medical Faculty, Department of Orthopedics and Traumatology.)
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of each of the theories to the pathogenesis of Charcot foot
is broadly detailed and discussed below.
Inflammation
Local inflammation is the indispensable factor that
triggers the course of events on a predisposing environ-
ment. The physiological balance between the pro and
anti-inflammatory cytokines that restrains the inflamma-
tory response to a necessary extent is compromised in
Charcot patients. Baumhauer’s findings support this
phenomenon based on the fact that in a Charcot patient
the modulation of immune system is disturbed in coun-
tenance of proinflammatory cytokines (6). Whatever is
the stimulant, the bone and soft tissues respond with an
acute-phase release of proinflammatory cytokines, tumor
necrosis factor-a (TNFa), and interleukin-1b (IL-1b).
They have found an increase in the amount of TNF-a,
IL-1b, and interleukin-6 (IL-6), whereas a decrease in the
levels of interleukin-4 and interleukin-10 known as anti-
inflammatory cytokines (39). An abnormally intense and
prolonged inflammatory response is inevitable under
these circumstances.
Increased amounts of proinflammatory cytokines,
especially TNFa is found to be responsible for triggering
another cytokine pathway that is centered on the poly-
peptide, the receptor activator of nuclear factor-kB
(NF-kB) ligand (RANKL). As a member of the TNF
superfamily, RANKL is the ligand that activates the
receptor of NF-kB (RANK). The activation of RANK
stimulates the intracellular pathways that end up by
formation of nuclear transcription factor NF-kB. The
expression of NF-kB induces osteoclast precursor cells
to differentiate into mature osteoclasts (20, 21). Thus,
NF-kB pathway is implicated in the excessive osteoclastic
activity in diabetic Charcot arthropathy (40, 41) along
with its involvement in many conditions that manifest
with osteolysis including glucocorticoid-induced osteo-
porosis, metastatic malignancy, periodontitis, prosthesis-
related osteolysis, and rheumatoid arthritis (20, 26).
RANKL activity is antagonized by Osteoprotegerin
(OPG), a soluble glycoprotein decoy receptor for RANK
ligand which effectively neutralizes its effects (20).
OPG’s expression is induced by NF-kB, as a self-limiting
agent of its proinflammatory function. The patients with
Charcot arthropathy displayed elevated RANKL/OPG
ratios fuelling the progression of the inflammation (Fig. 3)
(41, 42).
Osteoclasts play a key role in the course of Charcot
arthropathy as executer cells, responsible for imbalanced
bone turnover and eventually osteolysis. Macrophage
colony stimulating factor (M-CSF) is required for pre-
cursor cells in myeloid lineage to differentiate into bone
marrow macrophages, but the activation of NF-kBi s
crucial for their further differentiation, fusion into
multinucleated osteoclasts, activation, and survival (41).
However, the first cell line to dysfunction seems to be the
monocytes, the precursor cells of osteoclasts. With high
levels of proinflammatory cytokines, monocytes stimulate
T lymphocytes in an exaggerated way. In addition to
this, monocytes obtained from Charcot patients present
reduced secretion of anti-inflammatory cytokines, and
increased resistance to apoptosis (21, 42). This resistance
provided mainly by IL-1b and TNFa causes the persis-
tence of the abnormally intense and prolonged inflam-
matory response (3). Ndip et al. reported that IL-8 and
Granulocyte-Colony Stimulating Factor (GCSF) were
inducing monocytes into an osteoclastic differentiation
along with the RANKL/RANK pathway (41).
Pitocco et al. encountered a significant decrease in the
circulating levels of IGF-1 while investigating bipho-
sphonate’s efficacy in Charcot patients (43). IGF-1 is a
mediator of vasodilatation, and biphosphonate’s redu-
cing effect over IGF-1 could have a beneficial contribu-
tion to restrain proceeding inflammation.
Fig. 3. RANKL pathway in the pathophysiology of Charcot arthropathy.
(The copyright of the ﬁgure belongs to the authors.)
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It has long been suspected that the central nervous system
intervenes with the regulation and/or the modulation of
the bone metabolism (44). This function is mediated
through peptides that are synthesized in unmyelinated
sensory neurons and secreted from their peripheral
terminals in the bone tissue. However, this function differs
from the synaptic transmission as the signal transduction
by the neuropeptides is thought to be non-synaptic,
diffuse, and slow (45). The essential role of neuropeptides
in the bone metabolism is thoroughly studied by Offley
et al. (46). They reported that capcaisin-induced depletion
of neuropeptides such as Substance P (SP) and Calcitonin
Gene-Related Peptide (CGRP) in unmyelinated sensory
neurons of adult rats resulted in an increased bone loss
and fragility. The authors suggested that this effect could
be reversed by daily injections of CGRP (46).
CGRP is the most studied neuropeptide since evidences
suggest a direct action of CGRP regulating the cellular
activities ofosteoblasts. CGRP is shown to bind to its own
receptor and to increase intracellular cyclic AMP and
calcium in osteoblastic cells. Moreover, CGRP stimulates
cell proliferation, synthesis of cytokines, synthesis of
growth factors, and synthesis of collagen (40). Most of
the CGRP present in the circulation is released via non-
synaptic secretion from small sensory nerve terminals of
unmyelinated C type and small myelinated A-d-type nerve
fibers. These fibers are abundantly located in the perios-
teum, bone tissue, and bone marrow especially in the
epiphyseal trabecular bone (45). CGRP is also shown
to be expressed by osteoblasts endogenously, suggesting
the existence of an autocrine loop (45). CGRP has been
shown to inhibit proinflammatory cytokine produc-
tion and increase the release of IL-10 by monocytes.
Denervated Charcot foot is deprived of CGRP release
thus an important source of anti-inflammatory impulse is
compromised (21, 47).
Nitric oxide (NO) is a free radical gas that functions
as a secondary messenger molecule in many biological
pathways. Severalstudies suggest that NO has a reciprocal
effect on the modulation of bone metabolism (48). NO’s
inhibitory effect over the osteoclasts is demonstrated
in animal studies, observing NO being able to induce
apoptosis of pre-osteoclasts and decrease the resorbtive
action of the mature osteoclasts in mice (49). Diminished
expression of eNOS is observed in Charcot patients,
which leads to a suppression of the osteoclast activity
and contributes to a marked increase in the fragility of
osteoporotic bone (48). More recently Tan et al. studied
the biomechanical effects of the pulsatile fluid flow (PFF)
through the periosteocytic canaliculi (50). They demon-
strated that PFF plays a major role in preventing
osteocyte apoptosis, and this effect is mediated by NO.
Osteoclasts are attracted by apoptotic osteocytes resulting
in bone resorption. Thus, insufficient amounts of NO
production might induce osteocytes to apoptosis, enhan-
cing indirectly the osteoclast function. Other studies
supported NO’s biphasic effect on osteoclasts, suggesting
that low concentrations of NO potentiate bone resorption
while higher concentrations are inhibitory (51).
Sympathetic innervation of the bone and bone marrow
is demonstrated by monitorization of thyrosine hydro-
xylase activity, the rate-limiting enzyme of catecholamine
synthesis (46). Noradrenergic innervation of the bone
tissue is effective not only in regulating blood flow but
also in the modulation ofosteoblastic and osteoclastic cell
metabolism. Osteoblasts express b-2 adrenergic recep-
tors. Moreover, noradrenalin increases alkaline phospha-
tase activity and proliferation through a-1 receptors
expressed on the osteoblasts (23).
Microvascular structure and bone turnover
When Charcot first described the neuropathic arthropaty,
he implicated the increase in bone perfusion secondary
to the sympathetic denervation as responsible for bone
resorption (38). Jeffcoate improves this hypothesis further
by suggesting that Charcot arthropathy requires the
coexistence of a dense neuropathy with a relatively intact
peripheral circulation (26). The rarity of Charcot arthro-
pathy may be explained by the fact that it affects only the
limbs with the capacity to mount an inflammatory
response, in other words, to retain the ability to increase
blood flow in response to a particular stimulus (20).
Baker et al. studied the rate of maximum microvascular
hyperemia (MMH) in patients with diabetic neuropathy
and diabetic Charcot arthropathy and found that in
Charcot patients, MMH is relatively preserved and
significantly higher than patients with neuropathy alone
(52). Similarly, Shapiro et al. demonstrated increased
skin blood flow and vasomotion in both healthy control
and Charcot subjects, in contrast with diabetic neuro-
pathy patients (53). Those findings suggest that Charcot
patients preserve the ability to vasodilate as opposed to
patients with diabetic neuropathy alone, and it may be
an explanation why all patients with diabetic neuropathy
do not develop Charcot. However, peripheral arterial
disease seems to have a protective effect on the develop-
ment of Charcot arthropathy (24). This is probably due
to limited vasodilation capacity of the affected arteries.
Sympathetic vascular denervation increases local
arterio-venous shunt flow, which functions in body
thermoregulation in physiological conditions. Unregu-
lated shunts increase venous pressure and enhance fluid
filtration through capillary leakage (24). Consequently,
deep tissue edema increases intra-compartmental pres-
sure, compromises microcirculation, and causes a deep
tissue ischemia (54). Moreover, extensive connective tissue
edema impairs tensile strength and stability of tendons
and ligaments, predisposing the joints to subluxations and
dislocations.
The Charcot foot
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activity leads to an imbalance of constant remodeling
processes. An increase in alkaline phosphatase and
collagen residues, indicative of osteoclast activity, were
observed in the patients with acute Charcot arthropathy
(55, 56). However, in a recent study La Fontaine suggested
the possibility of a preexisting abnormal bone structure
predisposing diabetic patients for Charcot foot (5).
They have conducted histological examination of bone
specimens obtained from diabetic patients and observed
a distorted microstructure with fewer trabeculae and
fewer cells. Thus, the authors argued that the degen-
erative changes in the bone micro-architecture may not
be a consequence, but a cause of Charcot arthropathy
(Fig. 4) (5).
Although a low bone mineral density (BMD) is
observed in patients with type 1 diabetes, the BMD is
similar to or higher in type 2 diabetic patients than in
non-diabetic subjects (5). Yet, Charcot foot’s prevalence
does not seem to preponderate between types of diabetes
(18, 20). Christensen et al. reported significantly lower
BMD values obtained from the affected foot of chronic
Charcot patients whereas no difference was in the cal-
caneal BMD between acute Charcot patients and the
control group. Therefore, Charcot arthropathy does not
seem to affect the skeleton in general (57). Moreover,
biochemical indicators of bone turnover were also
evaluated in the same study and statistically significant
differences in osteocalcin concentrations reflecting in-
creased bone turnover were demonstrated in acute
Charcot foot (56).
A recent study demonstrated the development of
Charcot arthropathy after administration of high doses
of glucocorticoids (37). Glucocorticoids affect the bone
turnoverincountenanceofresorption,anddecreasedbone
formation may trigger or worsen Charcot arthropathy.
Vitamin D deficiency is accused of being preliminary
to the development of Charcot arthropathy (37). Hypo-
calcaemia occurs in vitamin D deficiency and this
stimulates parathyroid hormone (PTH) which in turn
depletes calcium from the bone causing osteopenia. The
level of 1,25(OH)2D3 is significantly lower in diabetic
patients and this decrease results in a less mineralized
bone formation, a smaller growth plate and an inade-
quate turnover, all being reversed by insulin treatment (49).
Hyperglycemia
The expression of RANKL is proven to be closely
associated with metabolic consequences of the diabetes.
Increased blood sugar potentiates free radical formation,
hyperlipidemia and advanced glycation end-products
(AGEs), triggering the RANK/RANKL cytokine system
(6). Moreover, an in vitro inhibitory effect of physiologi-
cal concentrations of insulin on the NF-kB and mono-
cyte chemoattractant protein 1 (MCP-1) is also reported
(57). This non-RANKL inhibitory mechanism is im-
paired in diabetic patients who are deprived of insulin.
However, those pathways may not be majorly effective
since the Charcot arthropathy is rare even in diabetic
neuropathy patients (58).
Hyperglycemia denaturates tendons and ligaments
through a non-enzymatic collagen glycation. This phe-
nomenon could cause tendon shortenings and thus,
Fig. 4. Cycle of pathophysiology of Charcot osteoarthropathy.
(The copyright of the ﬁgure belongs to the authors.)
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Moreover, since collagen is a structural component of the
bone, AGE-related modifications of collagen, may impair
the mechanical properties of bone itself, predisposing it
to fractures and dislocations (49, 59) (Figs. 3 and 4).
Genetics
Genes regulating OPG/RANK/RANKL axis and their
polymorphisms have already been indicated in the patho-
genesis of the osteoporosis (60). A correlation between
diabetic Charcot arthropathy and OPG gene polymorph-
isms is first suggested by Pitocco et al. (61). They have
investigated single-nucleotide polymorphisms (SNPs) on
the OPG gene and found two variations that could result
in both qualitative and quantitative alterations of OPG.
A strong association with Charcot arthropathy and the
polymorphisms of those alleles were also demonstrated.
Recently, Korzon-Burakowska et al. supported this asso-
ciation in their study conducted in the Polish popula-
tion (28). Their results agreed with the previous study
conducted in Italy (61), despite the differences in alleles
between Charcot patients and control groups did not
match among the two populations.
Discussion
The pathophysiological process that leads to an acute
Charcot foot episode is a very dynamic research topic.
New studies are added to the immense pool of literature
on this topic aiming to clarify and prevent the onset
and progression of this devastating complication. Recent
advances on the subject demonstrated that the neuro-
traumatic and neurotrophic theories both play a part and
contribute to development of the Charcot foot. However,
the question that still remains is why all patients with
diabetic neuropathy do not develop a Charcot foot?
A reasonable explanation to this question may enlighten
the pathogenesis substantially and thus, set forth a
possible way to avoid its onset.
In recent studies, many authors have emphasized the
disturbance of the inflammatory cycle in the core of
Charcot foot pathophysiology. Usually minor injuries
which are even unrecognized, local infection or a minor
surgery may prompt this sequence of events. Without the
protective behavior ensured by the pain, in the insensate,
neuropathic foot of a diabetic patient this cycle is flared
up by repeated traumatic events. Genetic variations that
affect the balance between pre- and anti-inflammatory
chemo-attractants may predispose a patient to Charcot
foot (28, 61). This theory which has been proposed by
two different studies conducted in different populations
is a breakthrough for researchers who dedicated their
work to Charcot foot. Genetic variations can explain a
patient’s tendency to pro-inflammatory status, and ulti-
mately may put forth a solid answer why a majority
of neuropathic patients are spared from Charcot
arthropathy.
Finally, it is often difficult to isolate and experiment
the contribution of a single factor in this complex and
multifactorial phenomenon. This fact precludes the con-
struction of experimental models to reveal single factor
contributions or gathering of adequate (appropriate)
control groups for blindedcontrol studies. This suggestion
can be adapted to Charcot foot that develops as a result of
a subsequent dysfunction concerning different systems
which cannot be separated and observed solely. This
stalemate can be addressed with prospective studies and
a larger number of patients.
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